[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-426802-105":59,"doc-detail-426802-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sarcopenia-among-older-adults-epidemiology-proteomics-technology-and-biomarkers-symposium-session","SARCOPENIA AMONG OLDER ADULTS - Epidemiology, Proteomics, Technology and Biomarkers - Symposium Session","","Research session focused on sarcopenia in older adults, integrating epidemiology, proteomics, technology-based monitoring, and biomarkers. It addresses methodological challenges in defining sarcopenia in population studies and the value of accurate, practical diagnostic criteria for estimating prevalence and impact. Incidence evidence from ages 66 to 90+ is reviewed using the ARIC cohort (2011–2023), alongside actigraphy for physical-activity tracking. Proteomic findings compare shared and distinct biological pathways, and longitudinal changes in the creatinine muscle index, a blood marker of muscle mass, support continuous monitoring and early intervention. ",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sarcopenia-among-older-adults-epidemiology-proteomics-technology-and-biomarkers-symposium-session/426802/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sarcopenia-among-older-adults-epidemiology-proteomics-technology-and-biomarkers-symposium-session/426802.png","ImageObject",300,407,{"name":92,"@type":93},"jay","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-05","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the session cover about sarcopenia in older adults?","Question",{"text":112,"@type":113},"It covers defining sarcopenia in population studies, evidence of incidence across older age ranges, actigraphy monitoring, proteomics, and biomarker-based longitudinal tracking.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is incidence of sarcopenia assessed in the session?",{"text":117,"@type":113},"Incidence data are presented for ages 66 to 90+ using the ARIC cohort from 2011 to 2023.",{"name":119,"@type":110,"acceptedAnswer":120},"What biomarkers or monitoring tools are highlighted?",{"text":121,"@type":113},"Actigraphy is used to track physical activity patterns, and the creatinine muscle index is discussed as a novel blood marker of muscle mass with longitudinal changes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},426802,1791166498,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":8,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":81},3985747858866,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","360 Innovation in Aging, 2025, Vol. 9, No. S2  \nSESSION 3105 (SYMPOSIUM)   \nAbstract citation ID: igaf122.1216  \nSARCOPENIA AMONG OLDER ADULTS:  \nEPIDEMIOLOGY, PROTEOMICS, TECHNOLOGY AND  \nBIOMARKERS  \nChair: Josef Coresh  \nCo-Chair: Shoshana Ballew  \nDiscussant: Jennifer Schrack  \nThis session delves into research in sarcopenia, a condition characterized by the loss of muscle mass and function in older adults, from epidemiology, proteomics, technology and biomarkers. The session begins with a discussion on the challenges and methodologies in defining sarcopenia within a population-based study of the oldest adults, highlighting the importance of accurate and practical diagnostic criteria in understanding its prevalence and impact.  \nFollowing this, data on the incidence of sarcopenia from age 66 to 90+ years, using theARIC cohort from 2011 to 2023, is presented to provide insights into the age-related progression of sarcopenia and its public health implications. The session then explores the use of actigraphy monitoring among older adults with sarcopenia, showcasing innovative approaches to tracking physical activity patterns that offer new avenues for early detection and management. The proteomics of sarcopenia is examined next, focusing on both shared and distinct biological pathways that contribute to its prevalence and future risk, shedding light on the molecular underpinnings and potential targets for intervention. Finally, longitudinal changes in the creatinine muscle index, a novel blood marker of muscle mass, among older adults are discussed, emphasizing the importance of continuous monitoring and early intervention in mitigating the adverse effects of muscle loss. Overall, the session provides a wide-ranging set of results in sarcopenia research and a discussion of the implications of this common and treatable condition in aging populations.","cbCaipHCOy8WPj6o","https://ap.wps.com/l/cbCaipHCOy8WPj6o","pdf",357671,"English","# Overview\n## Epidemiology and diagnostic criteria\n## Incidence across ages (ARIC 2011–2023)\n## Actigraphy-based monitoring\n## Proteomics and biological pathways\n## Creatinine muscle index and longitudinal biomarkers","[{\"question\":\"What does the session cover about sarcopenia in older adults?\",\"answer\":\"It covers defining sarcopenia in population studies, evidence of incidence across older age ranges, actigraphy monitoring, proteomics, and biomarker-based longitudinal tracking.\"},{\"question\":\"How is incidence of sarcopenia assessed in the session?\",\"answer\":\"Incidence data are presented for ages 66 to 90+ using the ARIC cohort from 2011 to 2023.\"},{\"question\":\"What biomarkers or monitoring tools are highlighted?\",\"answer\":\"Actigraphy is used to track physical activity patterns, and the creatinine muscle index is discussed as a novel blood marker of muscle mass with longitudinal changes.\"}]","SARCOPENIA AMONG OLDER ADULTS - Epidemiology, Proteomics, Technology and Biomarkers - Symposium Session | PDF",1790641854]